Argent BioPharma Sets April General Meeting for Shareholders

Argent Biopharma ( (AU:RGT) ) has issued an update.

Argent BioPharma has dispatched documentation for a General Meeting of shareholders scheduled for 10:00 a.m. AWST on 8 April 2026 in Subiaco, Western Australia. Shareholders are encouraged to participate either in person or by lodging proxies online by 10:00 a.m. AWST on 6 April 2026, with options to manage their meeting-related document preferences through the company’s share registry services.

The convening of the General Meeting signals an ongoing engagement with Argent BioPharma’s investor base as it advances its clinical pipeline and maintains governance processes. While specific resolutions are not detailed in the materials, the meeting framework underscores routine corporate oversight and offers stakeholders formal channels to influence company decisions and stay aligned with its strategic direction.

The most recent analyst rating on (AU:RGT) stock is a Hold with a A$0.05 price target. To see the full list of analyst forecasts on Argent Biopharma stock, see the AU:RGT Stock Forecast page.

More about Argent Biopharma

Argent BioPharma Ltd. (ASX: RGT) is a clinical-stage biopharmaceutical company developing nano-engineered medicines aimed at restoring balance between the nervous and immune systems. Its lead candidates, CannEpil for drug-resistant epilepsy and CimetrA for cytokine-driven inflammatory and autoimmune disorders, leverage proprietary delivery platforms designed to enhance penetration across the blood-brain and alveolar-capillary barriers, supported by EU-GMP manufacturing and late-stage clinical programs focused on urgent unmet needs in central nervous system and systemic inflammation.

Average Trading Volume: 193,929

Technical Sentiment Signal: Strong Sell

Current Market Cap: A$4.4M

For detailed information about RGT stock, go to TipRanks’ Stock Analysis page.